A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes
Phase of Trial: Phase I
Latest Information Update: 21 Feb 2019
Price : $35 *
At a glance
- Drugs Abaloparatide (Primary) ; Bevacizumab (Primary)
- Indications Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 14 Feb 2019 Status changed from not yet recruiting to recruiting.
- 14 Feb 2019 Planned initiation date changed from 1 Jan 2019 to 1 Mar 2019.
- 27 Nov 2018 New trial record